Research Article
Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy
Table 1
The relationship between SRSF9 gene expression and the prognosis of different cancers in PrognoScan.
| Gene | Dataset | Cancer type | Endpoint | Number | Cox value | HR | 95% CI (low-high) |
| SRSF9 | GSE1456-GPL97 | Breast cancer | RFS | 159 | 0.003805 | 3.91 | 1.55–9.86 | SRSF9 | GSE4922-GPL96 | Breast cancer | DFS | 249 | 0.007491 | 2.84 | 1.32–6.09 | SRSF9 | GSE4922-GPL96 | Breast cancer | DFS | 249 | 0.007793 | 2.52 | 1.28–4.99 | SRSF9 | GSE1456-GPL97 | Breast cancer | DSS | 159 | 0.012586 | 4.00 | 1.35–11.88 | SRSF9 | GSE31210 | Lung cancer | RFS | 204 | 0.027333 | 2.89 | 1.13–7.43 | SRSF9 | GSE9891 | Ovarian cancer | OS | 278 | 0.030832 | 1.70 | 1.05–2.74 | SRSF9 | GSE8970 | Blood cancer | OS | 34 | 0.030936 | 3.98 | 1.14–13.95 | SRSF9 | GSE1456-GPL96 | Breast cancer | DSS | 159 | 0.031512 | 3.03 | 1.10–8.32 | SRSF9 | HARVARD-LC | Lung cancer | OS | 84 | 0.033228 | 2.84 | 1.09–7.42 | SRSF9 | GSE4922-GPL97 | Breast cancer | DFS | 249 | 0.034675 | 2.05 | 1.05–4.00 | SRSF9 | GSE19234 | Skin cancer | OS | 38 | 0.035679 | 4.31 | 1.10–16.84 | SRSF9 | GSE11595 | Esophagus cancer | OS | 34 | 0.036602 | 2.33 | 1.05–5.15 | SRSF9 | GSE1456-GPL96 | Breast cancer | RFS | 159 | 0.039336 | 2.51 | 1.05–6.00 | SRSF9 | GSE1456-GPL97 | Breast cancer | OS | 159 | 0.043242 | 2.58 | 1.03–6.47 | SRSF9 | GSE17710 | Lung cancer | RFS | 56 | 0.044264 | 2.48 | 1.02–6.02 | SRSF9 | GSE3494-GPL96 | Breast cancer | DSS | 236 | 0.046057 | 2.40 | 1.02–5.66 |
|
|